Article
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas.
Cell reports. Medicine - 20 Jun 2023
Bredel Markus, Espinosa Lluís, Kim Hyunsoo, Scholtens Denise M, McElroy Joseph P, Rajbhandari Rajani, Meng Wei, Kollmeyer Thomas M, Malta Tathiane M, Quezada Michael A, Harsh Griffith R, Lobo-Jarne Teresa, Solé Laura, Merati Aran, Nagaraja Surya, Nair Sindhu, White Jaclyn J, Thudi Nanda K, Fleming Jessica L, Webb Amy, Natsume Atsushi, Ogawa Seishi, Weber Ruthild G, Bertran Joan, Haque S Jaharul, Hentschel Bettina, Miller C Ryan, Furnari Frank B, Chan Timothy A, Grosu Anca-Ligia, Weller Michael, Barnholtz-Sloan Jill S, Monje Michelle, Noushmehr Houtan, Jenkins Robert B, Rogers C Leland, MacDonald David R, Pugh Stephanie L, Chakravarti Arnab
Abstract excerpt
Genetic alterations help predict the clinical behavior of diffuse gliomas, but some variability remains uncorrelated. Here, we demonstrate that haploinsufficient deletions of chromatin-bound tumor suppressor NFKB inhibitor alpha (NFKBIA) display distinct patterns of occurrence in relation to other genetic markers and are disproportionately present at recurrence. NFKBIA haploinsufficiency is associated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.